Application | Comment | Organism |
---|---|---|
medicine | the presence of P-gp in various drug-resistant cancer cells can cause failure in chemotherapy, as it is able to transport a variety of anticancer drugs out of the cell | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
2-[4-(3-ethoxy-1-propenyl)phenyl]-4,5-bis-[4-(2-propylamino)phenyl]-1H-imidazole | i.e. OC144-093. Coadministration of OC144-093 with docetaxel enhances the oral bioavailability of docetaxel to a limited extent (8-26%) in humans, and has a good safety profile as well | Homo sapiens | |
9,10-dihydro-5-methoxy-9-oxo-N-{4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl}-4-acridine | i.e. GF120918. A good and safe P-gp inhibitor alternative for cyclosporin A in enhancing the oral bioavailability of paclitaxel | Homo sapiens | |
elacridar | GF120918 | Homo sapiens | |
KR30031 | - |
Homo sapiens | |
laniquidar | R101933 | Homo sapiens | |
additional information | the main mechanisms of P-gp inhibitors involves the regulation of P-gp expression by binding to drug binding sites or modulator binding sites | Homo sapiens | |
PSC833 | i.e. valspodar | Homo sapiens | |
tariquidar | XR9576 | Homo sapiens | |
verapamil | - |
Homo sapiens | |
zosuquidar | LY335979 | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Synonyms | Comment | Organism |
---|---|---|
MDR1 | - |
Homo sapiens |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.16 | - |
pH and temperature not specified in the publication | Homo sapiens | 2-[4-(3-ethoxy-1-propenyl)phenyl]-4,5-bis-[4-(2-propylamino)phenyl]-1H-imidazole |
General Information | Comment | Organism |
---|---|---|
physiological function | overexpression of P-gp is often associated with multidrug resistance, as it can efflux a wide range of large hydrophobic and amphiprotic substrates | Homo sapiens |